Abstract Number: 1446 • ACR Convergence 2022
Contrast Enhaced Articular Magnetic Resonance Imaging (MRI) and Health Related Quality of Life in SLE Patients
Background/Purpose: Joint involvement in SLE is the most frequent manifestation and shows a wide heterogeneity (1) . It has not a valid classification and it…Abstract Number: 1458 • ACR Convergence 2022
Systemic Lupus Erythematosus (SLE) Patients with Cognitive Impairment Experience More Fatigue Compared to Patients Without Impairment
Background/Purpose: Cognitive impairment (CI) is highly prevalent in patients with systemic lupus erythematosus (SLE). Objective prevalence rates are reported as 38% [range: 20% to 80%]…Abstract Number: 1459 • ACR Convergence 2022
Evolution of Subjective Cognitive Impairment Overtime in SLE Patients: Bayesian Longitudinal Item Response Theory Modelling
Background/Purpose: Subjective cognitive impairment (SCI) is a significant problem in SLE and there are a lack of studies assessing change over time in SCI. The…Abstract Number: 1449 • ACR Convergence 2022
Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
Background/Purpose: The burden of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are both the second largest in the world. Patients with SLE are…Abstract Number: 1457 • ACR Convergence 2022
Baseline Characteristics of a Longitudinal, Multinational, Multiethnic Study of Lupus Patients, with or Without Lupus Nephritis
Background/Purpose: Clinically evident kidney disease eventually occurs in up to one-half of SLE patients. The aim of this study is to describe sociodemographic, clinical, serological…Abstract Number: 1470 • ACR Convergence 2022
Work Disability and Function in Systematic Lupus Erythematosus (SLE): Results from a Mixed-Methods Exploratory Canadian Study
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystemic, autoimmune disease which can result in disability and mortality. A functional assessment tool that measures the…Abstract Number: 1464 • ACR Convergence 2022
Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects females of reproductive age but can affect patients later in life. Late-onset (LO)-SLE is defined as SLE diagnosed…Abstract Number: 1466 • ACR Convergence 2022
Cardiovascular Risk Assessment in Patients with Systemic Lupus Erythematosus: Comparison Between QRISK and aGAPSS Scores
Background/Purpose: Cardiovascular diseases (CVDs) represent one of the most life-threatening conditions that can affect SLE patients. Assessing the potential CVD risk of these patients is…Abstract Number: 1462 • ACR Convergence 2022
Exploring the Potential of Urine: Serum Fractional Excretion Ratios as Disease Biomarkers in Active Lupus Nephritis
Background/Purpose: The goal of this exploratory study is to determine if urine:serum fractional excretion ratios can outperform the corresponding urinary biomarker proteins in identifying active…Abstract Number: 1473 • ACR Convergence 2022
Unsupervised Clustering of Lupus Patient-Reported Outcome Data Identifies Patient Groups with Differences in SLEDAI and Physician Global Assessment
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous clinical presentations. Patient-reported outcomes (PROs) can aid in the measurement of the burden of…Abstract Number: 1472 • ACR Convergence 2022
Autoantibodies Against Tripartite-Motif 72 Protein (TRIM72) in Systemic Lupus Erythematosus Patients and in a Lupus Mouse Models with Myocarditis, Can Compromise Membrane Repair in Cardiomyocytes Potentially Contributing to Cardiovascular Disease Progression
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that typically manifests in multiple organs, with some of the most significant complications occurring in the…Abstract Number: 1474 • ACR Convergence 2022
Quinolinic Acid, a Kynurenine/Tryptophan Pathway Metabolite, Correlates with Abnormalities in Brain Structure and Function in SLE
Background/Purpose: Stimulation of the kynurenine/tryptophan pathway by interferons alpha and gamma, both known contributors to SLE pathogenesis, leads to a potentially neurotoxic imbalance of pathway…Abstract Number: 1415 • ACR Convergence 2022
Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Background/Purpose: Circulating bioactive lipids can provide information about the pathogenesis of specific diseases and potentially help predict therapeutic response. Choosing the right biological therapy earlier…Abstract Number: 1365 • ACR Convergence 2022
Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database
Background/Purpose: FDA approved belimumab, the first targeted biological treatment for SLE, in March 2011 for adults with active, seropositive SLE receiving standard therapy. The indicated…Abstract Number: 1220 • ACR Convergence 2022
Autonomic Dysfunction in Sjogren’s Disease
Background/Purpose: Sjogren's Disease (SjD) is a heterogenous autoimmune disease associated with debilitating symptoms. Autonomic dysfunction (AD) is common in SjD and may contribute to symptom…
- « Previous Page
- 1
- …
- 578
- 579
- 580
- 581
- 582
- …
- 2607
- Next Page »
